Envoy Medical, Inc. (NASDAQ: COCH) announced its financial results for the fiscal year ended December 31, 2025, revealing a net revenue increase to $241,000 from $225,000 in the previous year. The company reported significant operational advancements, including the receipt of FDA approval to expand its pivotal clinical trial for the Acclaim® Cochlear Implant to its final stage. This approval is based on promising data from the trial, which is expected to enhance the company's market position in the hearing health sector. Additionally, Envoy Medical successfully extinguished over $32 million in debt, thereby strengthening its balance sheet. The company also completed a transformational capital raise led by institutional healthcare investors, which is anticipated to support further developments in its innovative cochlear implant technology. CEO Brent Lucas expressed pride in the company's progress, highlighting the momentum gained in 2025 as a foundation for an exceptional start to 2026. The company aims to revolutionize hearing health with fully implanted solutions, addressing the unmet needs of millions worldwide. Envoy Medical's strategic outlook remains positive as it continues to gather data and prepare for its PMA application submission to the FDA.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.